Danaher Exceeds Q4 Earnings Guidance but Faces Market Skepticism
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 28 2026
0mins
Should l Buy DHR?
Source: CNBC
- Revenue Growth: Danaher's Q4 2025 revenue rose 4.6% year-over-year to $6.84 billion, surpassing the analyst consensus estimate of $6.81 billion, indicating strong performance in the medical equipment sector.
- Adjusted EPS: Adjusted earnings per share increased by 4.2% to $2.23, exceeding the market expectation of $2.15, reflecting the company's ongoing improvement in profitability.
- Cautious Market Outlook: Despite better-than-expected core revenue growth guidance, management's outlook for 2026 remains conservative, anticipating core revenue growth between 3% and 6%, highlighting uncertainty in market demand.
- Bioprocessing Recovery: The bioprocessing segment saw core revenue growth of 8%, driven by strong demand for consumables, indicating a strengthening recovery in this key market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DHR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DHR
Wall Street analysts forecast DHR stock price to rise
18 Analyst Rating
17 Buy
1 Hold
0 Sell
Strong Buy
Current: 194.750
Low
240.00
Averages
266.18
High
310.00
Current: 194.750
Low
240.00
Averages
266.18
High
310.00
About DHR
Danaher Corporation is a global life sciences and diagnostics innovator. The Company operates through three segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Danaher Reports Q1 2026 Results with Strong EPS Growth and Acquisition Plans
- Significant Earnings Growth: Danaher reported net earnings of $1.029 billion for Q1 2026, a 7.8% increase year-over-year, indicating strong performance in bioprocessing and life sciences, despite a weaker-than-typical respiratory season, showcasing the company's recovery capability.
- EPS Improvement: The adjusted EPS grew nearly 10% to $2.06, exceeding market expectations, reflecting the company's successful execution in driving productivity and innovation, which bolsters investor confidence.
- Acquisition Announcement: Danaher announced its intention to acquire Masimo Corporation, a leader in acute care monitoring solutions, which is expected to enhance Masimo's performance through Danaher's global scale and business system, further expanding market share.
- Optimistic Future Outlook: The company anticipates core revenue growth of 3% to 6% for the full year 2026 and has raised its adjusted EPS guidance to a range of $8.35 to $8.55, demonstrating strong cash flow and capital deployment capacity, enhancing the potential for long-term shareholder value creation.
See More
Danaher Corporation Reports Strong EPS Beat Despite Revenue Miss
- Earnings Beat: Danaher Corporation (DHR) reported a non-GAAP EPS of $2.06, exceeding market expectations by $0.12, indicating strong profitability despite challenges in revenue generation.
- Revenue Miss: The company’s revenue of $5.95 billion fell short of expectations by $50 million, suggesting potential headwinds in certain business segments amid the current economic climate, which could impact future performance.
- Long-Term Investment Appeal: Despite the revenue miss, Danaher remains an attractive option for long-term dividend growth investors due to its consistent profitability and commitment to dividend payments, reinforcing investor confidence.
- Market Dynamics: The addition of Ecolab and GE Vernova to the Mar Vista U.S. Quality Premier fund, along with the exit of Salesforce and SAP, highlights shifting market dynamics that could influence investor sentiment and strategic positioning in the healthcare sector.
See More
Danaher Raises Full-Year Earnings Outlook Amid Mixed Q1 Results
- Earnings Outlook Raised: Danaher has raised its non-GAAP diluted EPS outlook to a range of $8.35 to $8.55, with a midpoint of $8.45, surpassing the consensus estimate of $8.40, indicating strong confidence in future profitability.
- Revenue Miss: Despite a ~4% YoY revenue growth to $5.95 billion in Q1, the figure fell short of forecasts by $50 million, primarily due to a ~2% YoY contraction in the Diagnostics segment, which negatively impacted overall performance.
- Segment Growth: The Biotechnology and Life Sciences segments achieved ~12% and ~4% YoY growth, respectively, contributing $1.74 billion and $1.80 billion to revenue, both exceeding market expectations, highlighting the company's strong performance in these areas.
- Operational Efficiency Improvement: Danaher's non-GAAP EPS grew ~10% YoY to $2.06, beating Street forecasts by $0.12, while the adjusted operating margin improved by 60 basis points to 30.2%, reflecting enhancements in cost control and profitability.
See More
Danaher Reports First Quarter Earnings Growth
- Earnings Growth: Danaher Corp. reported a first-quarter net income of $1.029 billion, translating to $1.45 per share, which marks a significant increase from last year's $954 million and $1.32 per share, indicating strong performance in the market.
- Strong Adjusted Earnings: Excluding items, Danaher reported adjusted earnings of $2.06 per share, demonstrating sustained profitability in its core operations and further solidifying its competitive position in the industry.
- Revenue Increase: The company's revenue for the first quarter reached $5.951 billion, up 3.7% from $5.741 billion last year, reflecting a continued rise in demand for its products and services, driving overall business growth.
- Positive Outlook: Danaher provided full-year EPS guidance of $8.35 to $8.55 and revenue growth expectations of 3% to 6%, indicating confidence in future performance and anticipated benefits from increasing market demand.
See More
Danaher Q1 Earnings Beat Expectations with Adjusted Guidance Increase
- Earnings Beat: Danaher reported a Q1 non-GAAP EPS of $2.06, exceeding expectations by $0.12, indicating strong performance in the healthcare sector and boosting investor confidence.
- Revenue Growth Slows: The company generated $5.95 billion in revenue, a 3.7% year-over-year increase, but fell short of expectations by $50 million, reflecting challenges from increased market competition and demand fluctuations.
- Optimistic Outlook: Danaher anticipates low-single-digit percentage growth in non-GAAP core revenue for Q2 2026, suggesting a cautiously optimistic management outlook despite economic uncertainties.
- Guidance Increase: The company raised its full-year adjusted diluted net earnings per share guidance to a range of $8.35 to $8.55, surpassing the consensus of $8.40, demonstrating confidence in profitability and potential for sustained growth.
See More
Major Earnings Reports Expected Before Tuesday's Open
- Earnings Release Preview: Major companies including General Electric (GE), UnitedHealth Group (UNH), 3M Company (MMM), and RTX Corporation (RTX) are set to report earnings before Tuesday's market open, which is expected to influence market sentiment.
- Additional Earnings Reports: In addition to the aforementioned firms, Halliburton (HAL) and several others such as DGX, DHI, and DHR will also release earnings, potentially impacting investor decisions.
- Market Focus: Investors will closely monitor these earnings reports to assess company performance and future outlooks, which could affect stock market trends and investment strategies.
- Earnings Season Calendar: Seeking Alpha offers a comprehensive earnings season calendar, assisting investors in tracking key earnings release dates to optimize their investment strategies.
See More
Danaher Reports Q1 2026 Results with Strong EPS Growth and Acquisition Plans
- Significant Earnings Growth: Danaher reported net earnings of $1.029 billion for Q1 2026, a 7.8% increase year-over-year, indicating strong performance in bioprocessing and life sciences, despite a weaker-than-typical respiratory season, showcasing the company's recovery capability.
- EPS Improvement: The adjusted EPS grew nearly 10% to $2.06, exceeding market expectations, reflecting the company's successful execution in driving productivity and innovation, which bolsters investor confidence.
- Acquisition Announcement: Danaher announced its intention to acquire Masimo Corporation, a leader in acute care monitoring solutions, which is expected to enhance Masimo's performance through Danaher's global scale and business system, further expanding market share.
- Optimistic Future Outlook: The company anticipates core revenue growth of 3% to 6% for the full year 2026 and has raised its adjusted EPS guidance to a range of $8.35 to $8.55, demonstrating strong cash flow and capital deployment capacity, enhancing the potential for long-term shareholder value creation.
See More
Danaher Corporation Reports Strong EPS Beat Despite Revenue Miss
- Earnings Beat: Danaher Corporation (DHR) reported a non-GAAP EPS of $2.06, exceeding market expectations by $0.12, indicating strong profitability despite challenges in revenue generation.
- Revenue Miss: The company’s revenue of $5.95 billion fell short of expectations by $50 million, suggesting potential headwinds in certain business segments amid the current economic climate, which could impact future performance.
- Long-Term Investment Appeal: Despite the revenue miss, Danaher remains an attractive option for long-term dividend growth investors due to its consistent profitability and commitment to dividend payments, reinforcing investor confidence.
- Market Dynamics: The addition of Ecolab and GE Vernova to the Mar Vista U.S. Quality Premier fund, along with the exit of Salesforce and SAP, highlights shifting market dynamics that could influence investor sentiment and strategic positioning in the healthcare sector.
See More
Danaher Raises Full-Year Earnings Outlook Amid Mixed Q1 Results
- Earnings Outlook Raised: Danaher has raised its non-GAAP diluted EPS outlook to a range of $8.35 to $8.55, with a midpoint of $8.45, surpassing the consensus estimate of $8.40, indicating strong confidence in future profitability.
- Revenue Miss: Despite a ~4% YoY revenue growth to $5.95 billion in Q1, the figure fell short of forecasts by $50 million, primarily due to a ~2% YoY contraction in the Diagnostics segment, which negatively impacted overall performance.
- Segment Growth: The Biotechnology and Life Sciences segments achieved ~12% and ~4% YoY growth, respectively, contributing $1.74 billion and $1.80 billion to revenue, both exceeding market expectations, highlighting the company's strong performance in these areas.
- Operational Efficiency Improvement: Danaher's non-GAAP EPS grew ~10% YoY to $2.06, beating Street forecasts by $0.12, while the adjusted operating margin improved by 60 basis points to 30.2%, reflecting enhancements in cost control and profitability.
See More
Danaher Reports First Quarter Earnings Growth
- Earnings Growth: Danaher Corp. reported a first-quarter net income of $1.029 billion, translating to $1.45 per share, which marks a significant increase from last year's $954 million and $1.32 per share, indicating strong performance in the market.
- Strong Adjusted Earnings: Excluding items, Danaher reported adjusted earnings of $2.06 per share, demonstrating sustained profitability in its core operations and further solidifying its competitive position in the industry.
- Revenue Increase: The company's revenue for the first quarter reached $5.951 billion, up 3.7% from $5.741 billion last year, reflecting a continued rise in demand for its products and services, driving overall business growth.
- Positive Outlook: Danaher provided full-year EPS guidance of $8.35 to $8.55 and revenue growth expectations of 3% to 6%, indicating confidence in future performance and anticipated benefits from increasing market demand.
See More
Danaher Q1 Earnings Beat Expectations with Adjusted Guidance Increase
- Earnings Beat: Danaher reported a Q1 non-GAAP EPS of $2.06, exceeding expectations by $0.12, indicating strong performance in the healthcare sector and boosting investor confidence.
- Revenue Growth Slows: The company generated $5.95 billion in revenue, a 3.7% year-over-year increase, but fell short of expectations by $50 million, reflecting challenges from increased market competition and demand fluctuations.
- Optimistic Outlook: Danaher anticipates low-single-digit percentage growth in non-GAAP core revenue for Q2 2026, suggesting a cautiously optimistic management outlook despite economic uncertainties.
- Guidance Increase: The company raised its full-year adjusted diluted net earnings per share guidance to a range of $8.35 to $8.55, surpassing the consensus of $8.40, demonstrating confidence in profitability and potential for sustained growth.
See More
Major Earnings Reports Expected Before Tuesday's Open
- Earnings Release Preview: Major companies including General Electric (GE), UnitedHealth Group (UNH), 3M Company (MMM), and RTX Corporation (RTX) are set to report earnings before Tuesday's market open, which is expected to influence market sentiment.
- Additional Earnings Reports: In addition to the aforementioned firms, Halliburton (HAL) and several others such as DGX, DHI, and DHR will also release earnings, potentially impacting investor decisions.
- Market Focus: Investors will closely monitor these earnings reports to assess company performance and future outlooks, which could affect stock market trends and investment strategies.
- Earnings Season Calendar: Seeking Alpha offers a comprehensive earnings season calendar, assisting investors in tracking key earnings release dates to optimize their investment strategies.
See More
